Regulatory
Correction refers to change of category of press release from non-regulatory to regulatory. All other information is unchanged relative to previous version.
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that, following the national approval in Poland, the company has now received national market approvals in all 15 countries included in the Decentralised Procedure (DCP) approval receive…
Regulatory
Sales growth in our direct markets despite temporary market headwinds
Regulatory
According to the principles for the appointment of the Nomination Committee in Sedana Medical AB (publ), the Nomination Committee for the annual general meeting 2023 shall be composed of members appointed by the three largest shareholders as of Septe…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company will hold a scientific symposium during ESICM Lives 2022, the annual congress of the European Society of Intensive Care Medicine. Additional data on inhaled sedation wil…
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the third quarter 2022 in an audiocast on October 25 at 13.30 CET.
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has received Medical Device Regulation (MDR) certification, which secures EU market access for Sedaconda® ACD under the new MDR regulation, well ahead of the deadline in…
Regulatory
Committed to change the standard of care, with commercial progress and a strong balance sheet.
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the second quarter 2022 in an audiocast on July 21 at 13.30 CET.
Regulatory
Today, the annual general meeting of Sedana Medical AB (publ) (SEDANA: FN Stockholm) was held. In order to counteract the spreading of the corona virus, the general meeting was held only through advance voting (so-called postal voting) in accordance…
Regulatory
First patient enrolled in US clinical program
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the first patient has been enrolled in the company’s US clinical studies. The two identical Phase III studies, INSPiRE-ICU 1 and 2, aim to confirm the efficacy and safety of inhaled…
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the first quarter 2022 in an audiocast on April 28 at 13.30 CET.
Regulatory
The correction refers to incorrect reference to the Market Abuse Regulation, which was removed in this press release.
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) published its Annual Report 2021.
Regulatory
The shareholders in Sedana Medical AB (publ), reg. no. 556670-2519, are hereby given notice to attend the annual general meeting to be held Wednesday, 11 May 2022. In order to counteract the spreading of the corona virus, the board of directors of th…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that a post hoc analysis on the Sedaconda study will be presented as a poster at the world’s largest conference for intensive care and emergency medicine, ISICEM, in Brussels on March 22…
Regulatory
Sales at an all-time-high provide a strong platform for launch
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the first bottles of Sedaconda (isoflurane) have been delivered to customers. The first sales were made in the company’s largest market Germany.